Trinity Biotech Partners with Bioinformatics Firm to Advance Prostate Cancer Test
Trinity Biotech plc has announced a strategic collaboration with a leading bioinformatics company to advance the analysis of clinical trial data for its EpiCapture prostate cancer test. The partnership aims to enhance the test’s ability to detect DNA methylation patterns associated with high-grade prostate cancer, supporting its development towards regulatory approval and commercialization. This initiative is part of Trinity Biotech’s strategy to expand its portfolio of innovative diagnostic technologies.
Trinity Biotech plc has announced a strategic collaboration with a leading bioinformatics company to advance the analysis of clinical trial data for its EpiCapture prostate cancer test. The partnership will utilize advanced bioinformatics tools to enhance the test’s ability to detect DNA methylation patterns associated with high-grade prostate cancer, supporting its development towards regulatory approval and commercialization. This initiative aims to provide a non-invasive alternative for monitoring prostate cancer progression and is part of Trinity Biotech’s broader strategy to expand its portfolio of innovative diagnostic technologies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-003888), on November 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
